Objective
To evaluate the association between serum levels of DDE and AD and whether the apolipoprotein E (APOE) genotype modifies the association.

Design, Setting, and Participants
A case-control study consisting of existing samples from patients with AD and control participants from the Emory University Alzheimer’s Disease Research Center and the University of Texas  Southwestern Medical School’s Alzheimer’s Disease Center. Serum levels  of DDE were measured in 79 control and 86 AD cases.

Main Outcomes and Measures
Serum DDE levels, AD diagnosis, severity of AD measured by the Mini-Mental State Examination score, and interaction with APOE4 status.

Results
Levels of DDE were 3.8-fold higher in the serum of those with
AD (mean [SEM], 2.64 [0.35] ng/mg cholesterol) when compared with
control participants (mean [SEM], 0.69 [0.1] ng/mg cholesterol; P
< .001). The highest tertile of DDE levels was associated with an
odds ratio of 4.18 for increased risk for AD (95% CI, 2.54-5.82; P < .001) and lower Mini-Mental State Examination scores (−1.605; range, −3.095 to −0.114; P
< .0001). The Mini-Mental State Examination scores in the highest  tertile of DDE were −1.753 points lower in the subpopulation carrying an APOE ε4 allele compared with those carrying an APOE ε3 allele (Pinteraction = .04). Serum levels of DDE were highly correlated with  brain levels of DDE (ρ = 0.95). Exposure of human neuroblastoma cells to DDT or DDE increased levels of amyloid precursor protein.

Conclusions and Relevance
Elevated serum DDE levels are associated with an increased risk for AD and carriers of an APOE4
ε4 allele may be more susceptible to the effects of DDE. Both DDT and DDE increase amyloid precursor protein levels, providing mechanistic plausibility for the association of DDE exposure with AD. Identifying people who have elevated levels of DDE and carry an APOE ε4 allele may lead to early identification of some cases of AD.